GET DAILY SIGNALSHalozyme (HALO) Delivers +39% Revenue Growth in Q3 2026 Earnings
Key Takeaways
- Total revenue reached $493 million in the third quarter of 2026, up 39% year over year and ahead of the analyst consensus estimate of roughly $487 million.
- Adjusted (non-GAAP) earnings per share came in at $2.39, topping the consensus estimate of $2.28 by $0.11.
- Royalty revenue, the company's most closely watched metric, surged 44% year over year to a record $341 million.
- Management raised its full-year 2026 guidance across revenue, adjusted earnings per share, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).
- Despite the broad beat, shares fell about 6% in after-hours trading as the raised guidance largely matched already-elevated investor expectations.
Understanding the Earnings Context
Halozyme Therapeutics derives the majority of its revenue from royalties tied to its ENHANZE drug-delivery technology, which enables the subcutaneous administration of large-molecule biologic therapies. Because the company's top line is directly linked to the commercial success of partner products such as Johnson & Johnson's DARZALEX SC, argenx's VYVGART Hytrulo, and Roche's Phesgo, each quarterly report offers investors a real-time read on the durability and diversification of those royalty streams. The third quarter of 2026 was significant because it tested whether the momentum that drove a record second quarter could be sustained, and whether management's guidance would keep pace with a stock that had already climbed sharply in 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
Halozyme reported third-quarter 2026 total revenue of $493 million, a 39% increase from $354 million in the prior-year period and slightly above the consensus estimate of approximately $487 million. Royalty revenue climbed 44% year over year to a record $341 million, driven by continued uptake of ENHANZE-enabled products including VYVGART Hytrulo, DARZALEX SC, and Phesgo.
Adjusted (non-GAAP) diluted earnings per share rose to $2.39, beating the consensus estimate of $2.28 by $0.11 and up from $1.72 in the same quarter a year earlier. GAAP diluted earnings per share was $2.01, while net income increased 41% year over year to approximately $247 million. Adjusted EBITDA reached $336.2 million, reflecting a 68.2% margin.
Management also raised its full-year 2026 outlook. The company now expects total revenue of $1.860 billion to $1.925 billion, adjusted EBITDA of $1.240 billion to $1.290 billion, and adjusted diluted earnings per share of $8.75 to $9.05. From what I see, these figures reflect solid execution on the core royalty business.
Market Reaction and Investor Sentiment
Heading into the report, investor expectations were high: HALO shares had surged roughly 95% year to date, reflecting confidence in the company's royalty-driven growth model. The results themselves exceeded Wall Street's estimates across revenue, earnings per share, and adjusted EBITDA, but the stock still fell approximately 6% in after-hours trading.
The decline illustrates how much of the good news was already priced in. Although management raised full-year guidance, the updated midpoint for revenue and adjusted earnings per share landed only modestly above consensus, disappointing investors who had anticipated a larger step-up. The muted response suggests the market is now looking beyond near-term royalty beats and toward proof points on newer growth engines.
Forward Outlook and Key Factors to Monitor
Halozyme enters the final stretch of 2026 with raised full-year guidance and a royalty portfolio that is broadening beyond its flagship products. The company expanded ENHANZE collaboration agreements with argenx, Incyte, and Johnson & Johnson during the quarter, and three ENHANZE programs advanced into Phase 1 clinical development, bringing total products in development to twelve.
Investors will be watching several factors in the quarters ahead. First, the trajectory of newer launched products such as OCREVUS, Opdivo, TECENTRIQ, and RYBREVANT will indicate how quickly Halozyme can offset any future royalty step-downs on more mature therapies as patents approach expiration around 2029. Second, the company's newer HyperCon and Aerocon hyperconcentration platforms represent a longer-term opportunity, with the first two HyperCon products expected to enter Phase 1 clinical trials in the first half of 2027. I’m watching this closely as these developments could shape the next phase of growth.
Additional considerations include the ongoing litigation with Merck over subcutaneous formulations, which management has described as largely upside, as well as the pace of new collaboration signings and milestone activity. Cost trends also bear watching, as research and development and selling expenses have risen alongside the company's investments in new platforms. For now, the core ENHANZE royalty business continues to compound, but the market's muted reaction to a strong quarter signals that sustaining the stock's momentum may require clear progress on the next generation of growth drivers.
Integrating AI Tools into Research
In my regular analysis, I find Tickeron’s AI Screener particularly useful for quickly scanning technical patterns, fundamentals, and industry comparisons. It allows me to filter thousands of stocks and ETFs efficiently, helping spot trends or breakout candidates that complement traditional earnings reviews. This kind of tool has become a practical part of evaluating opportunities like HALO without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HALO in +2.09% Uptrend, growing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HALO advanced for three days, in 276 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on HALO as a result. In 55 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for HALO just turned positive on October 15, 2026. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in 25 of 35 cases over the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 258 of 328 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 60 cases where HALO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
HALO broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HALO's P/B Ratio (103.059) is slightly higher than the industry average of (2.904). P/E Ratio (36.715) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (7.968) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology
Advertisement